Pharmacological and metabolic effects of Bifidobacterium triple viable capsules and Five-animal Play in patients with impaired glucose tolerance.

All three treatments (aerobic exercise, Five-animal Play, and Bifidobacterium triple viable capsules) improved glucose parameters in patients with impaired glucose tolerance.

• Ninety persons with IGT participated in this randomized, parallel-group clinical trial.
• Interventions were administered for four weeks.
• All treatments significantly lowered FBG, 2hFBG, HbA1c, fasting insulin, and HOMA-IR (P<0.05).
• Measurements were taken before and during therapy.

All three treatments improved lipid indices in patients with impaired glucose tolerance.

• Reductions were observed in total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) across all treatment groups.
• High-density lipoprotein cholesterol (HDL-C) increased in all treatment groups.
• Improvements were statistically significant (P<0.05).
• The intervention period was four weeks.

Five-animal Play produced greater reductions in FBG, 2hFBG, and HOMA-IR compared to low-intensity aerobic exercise.

• Five-animal Play generated higher decreases in FBG, 2hFBG, and HOMA-IR than aerobic exercise (P<0.05).
• Five-animal Play also produced a more significant decline in Wnt5a compared to aerobic exercise (P<0.05).
• The exercise compared was described as low-intensity aerobic activity.

Outcomes in the Five-animal Play group were comparable to those in the probiotic (Bifidobacterium triple viable capsules) group.

• No statistically significant differences between Five-animal Play and the probiotic group were reported.
• Both groups showed similar effects on glucose-lipid metabolism and GLP-1/Wnt5a/Sfrp5 signaling outcomes.
• The probiotic used was Bifidobacterium triple viable capsules administered over four weeks.

No adverse responses or organ toxicities were observed with any of the three interventions.

• There were no negative responses or toxicities to the kidneys or liver reported for any treatment group.
• Safety was assessed across all ninety participants over the four-week intervention period.
• This finding supports the safety profile of Five-animal Play as a non-pharmacological intervention.

The study assessed GLP-1/Wnt5a/Sfrp5 signaling as a mechanistic pathway for the interventions' effects on glucose metabolism.

• Circulating GLP-1, Wnt5a, and Sfrp5 were measured before and during therapy.
• Wingless-type MMTV integration site family member 5a/secreted frizzled-related protein 5 (Wnt5a/Sfrp5) signaling and GLP-1 modulation were identified as possible treatment approaches.
• Five-animal Play produced a more significant decline in Wnt5a compared to aerobic exercise (P<0.05).
• The study design was a randomized, parallel-group clinical trial with ninety IGT participants.